Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
Open Access
- 23 January 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 123 (4), 554-561
- https://doi.org/10.1182/blood-2013-09-527044
Abstract
Key Points. AMG 330 cytotoxicity against AML cells is proportional to the level of CD33 expression but is not affected by ABC transporter activity.AMG 330 cytoKeywords
This publication has 46 references indexed in Scilit:
- Targeting T cells to tumor cells using bispecific antibodiesCurrent Opinion in Chemical Biology, 2013
- Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapyBest Practice & Research Clinical Haematology, 2012
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood, 2012
- Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicinLeukemia, 2012
- Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AMLBlood, 2012
- Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceBiochemical Pharmacology, 2012
- CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyBlood, 2007
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-γ1 in acute myeloid leukemia cellsLeukemia, 2004
- Clonal Development, Stem-Cell Differentiation, and Clinical Remissions in Acute Nonlymphocytic LeukemiaNew England Journal of Medicine, 1987